Immunicum: MERECA Update Confirms Ilixadencel Benefit

Research Note

2021-02-22

09:31

Redeye views today’s update from the MERECA as a positive and expected confirmation of previously reported results. We see no material changes to our valuation at this point.

NE

Niklas Elmhammer

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.